ZOMETA® Reduces Skeletal-Related Events From Bone Metastases In Renal Cell Carcinoma
Home


About ZOMETA
Breast Cancer
Lung Cancer
Prostate Cancer
Renal Cell Carcinoma
Multiple Myeloma

ZOMETA Patient Case Studies

Zometa Dosing & Administration

ZOMETA Safety & Tolerability

ZOMETA Clinical News

ZOMETA For Your Patients

Professional Resource Center

ZOMETA Around the World
Videos
View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

 
European Summary of Product Characteristics
For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics
 
About ZOMETA®: Renal Cell Carcinoma About ZOMETA: defend against SREs across a broad range of tumor types
Threat of SREs What are SREs ZOMETA® reduces SREs Dose ZOMETA® every 3 to 4 weeks References
Page  1 2


  ZOMETA® effectively helps to protect patients with renal cell carcinoma from the threat of SREs



Efficacy of ZOMETA vs placebo in patients with advanced renal cell carcinoma2
NR=not reached.



  • ZOMETA significantly extended time to first SRE vs placebo (median not reached vs 72 days, P=.006)2
  • ZOMETA reduced the percentage of patients who experienced an SRE by 50% vs placebo (P=.015)2

  ZOMETA can delay and reduce SREs in patients with renal cell carcinoma and bone  metastases2


Page  1 2